New Zealand’s pharmaceutical regulator, Medsafe, has approved two psychiatrists to prescribe pharmaceutical-grade MDMA to patients suffering from severe post-traumatic stress disorder, making the country the second in the world to permit the controlled therapeutic use of the psychedelic drug. The decision, announced Friday, was granted on an individual clinician basis rather than as a broad class authorization, distinguishing New Zealand’s approach from earlier moves abroad.
Under the approval, the two named psychiatrists will be permitted to administer MDMA in tightly controlled clinical settings to patients who have not responded adequately to existing PTSD treatments. Medsafe did not authorize a wider class of prescribers, opting instead to vet clinicians individually before extending prescribing rights. The regulator’s decision was confirmed in a statement reported by The Guardian.
The approval follows Australia’s 2023 decision to permit psychedelics, including MDMA, for the treatment of PTSD and treatment-resistant depression. Australia’s path was characterized by a broader rescheduling that opened prescribing to authorized clinicians meeting specified conditions. New Zealand’s narrower model means that, for now, only two psychiatrists in the country can legally offer MDMA-assisted therapy, with any expansion requiring further regulatory review.
What happened
Medsafe granted section 29 approvals under New Zealand’s Medicines Act 1981 to two psychiatrists, allowing them to prescribe unapproved or restricted medicines for individual patients in defined circumstances. The approvals specifically cover pharmaceutical-grade MDMA to be used as an adjunct to psychotherapy for adults diagnosed with severe PTSD who have not achieved adequate clinical response from standard treatments, including trauma-focused cognitive behavioral therapy and approved pharmacological options such as selective serotonin reuptake inhibitors.
Treatment under the approvals must be delivered in supervised clinical settings and combined with structured psychological support before, during, and after dosing sessions. The two clinicians are required to comply with protocols covering patient screening, dosing, monitoring during acute drug effects, and post-session integration therapy.
Why it matters
The decision carries significance on several fronts. It represents the first formal regulatory green light in New Zealand for a psychedelic compound to be used in mainstream psychiatric practice, signaling a willingness among New Zealand authorities to consider drug-assisted therapies for serious mental health conditions where conventional treatment options have fallen short. PTSD is associated with substantial disability, and a meaningful subset of patients does not respond to first-line therapies, leaving clinicians with limited options.
The model chosen by Medsafe also matters. By approving individual psychiatrists rather than authorizing a wider class of prescribers or rescheduling MDMA more broadly, the regulator has signaled a cautious posture that prioritizes oversight and clinician accountability over speed of access. This contrasts with Australia’s more permissive framework and places New Zealand in a position where the early clinical experience can be closely monitored before any expansion is considered.
Background and context
The clinical case for MDMA-assisted therapy has been built over more than a decade of research, including phase 2 and phase 3 trials conducted by organizations such as the Multidisciplinary Association for Psychedelic Studies (MAPS) and its public benefit corporation successor. Trial data reported in peer-reviewed journals, including Nature Medicine, have indicated that MDMA paired with structured psychotherapy produced clinically meaningful reductions in PTSD symptom severity in participants with severe and treatment-resistant presentations. Regulatory bodies in the United States have not approved MDMA for PTSD treatment; the Food and Drug Administration declined to approve an MDMA-assisted therapy application in 2024, requesting additional data.
Australia’s Therapeutic Goods Administration reclassified MDMA in 2023 to permit its use by authorized psychiatrists for PTSD and treatment-resistant depression, making it the first country to legalize psychedelic-assisted therapy at a national level. The move attracted international attention and prompted debate among clinicians, researchers, and policymakers about the appropriate regulatory model, the training required for therapists, and the infrastructure needed to deliver supervised psychedelic sessions safely.
New Zealand’s Medsafe has historically taken a conservative approach to medicines not yet approved by major overseas regulators. The use of section 29 of the Medicines Act to approve individual prescribers is a mechanism that allows named clinicians to prescribe medicines that have not been consented for general marketing, typically in situations where conventional approved treatments have been exhausted. The same provision has been used to provide access to other restricted or experimental medicines on a named-patient basis.
Advocates of MDMA-assisted therapy have argued that the drug’s pharmacological effects, including increased openness, reduced fear response, and enhanced emotional engagement, may make it easier for patients with PTSD to process traumatic memories during psychotherapy. Critics have pointed to the potential for adverse psychological effects, cardiovascular risks, and the challenges of ensuring that therapy is delivered by adequately trained clinicians in appropriate settings.
Analysis: New Zealand’s psychiatrist-by-psychiatrist approval model reflects a regulatory posture that prioritizes control and oversight over rapid scaling. By approving only two named clinicians at this stage, Medsafe retains the ability to scrutinize prescribing practices, audit outcomes, and respond to any adverse events without having to reverse a broader class authorization. The trade-off is access: patients outside the catchment of the two approved psychiatrists, or who do not meet the strict clinical criteria, will not benefit from the decision in its current form. Capacity for MDMA-assisted therapy is also constrained by the time-intensive nature of supervised sessions, which typically run for several hours and require integration therapy over multiple visits.
Analysis: The decision will likely sharpen international scrutiny of clinical outcomes. Regulators in jurisdictions that have so far declined to authorize MDMA for therapeutic use, including the United States and most European countries, will be watching how the first cohorts of New Zealand patients fare in real-world settings outside the controlled conditions of clinical trials. If documented results align with earlier trial data and no serious safety signals emerge, the New Zealand experience may be cited by advocates pressing for broader authorization elsewhere. Conversely, any adverse events, equivocal results, or evidence of off-label drift would reinforce the position of regulators and medical bodies that have so far maintained a more restrictive stance.
Analysis: The economic and structural questions raised by the decision remain unresolved. MDMA-assisted therapy is labor-intensive and requires specially trained therapists, supervised dosing environments, and extended clinical contact. None of the existing New Zealand public funding pathways have been confirmed as covering the treatment, meaning patients may need to pay privately, raising equity concerns about who can realistically access care. The cost of building the workforce and infrastructure to deliver the therapy at scale, should authorization expand, is not addressed by the current decision.
What to watch next
The two approved psychiatrists are expected to begin treating eligible patients under the protocols attached to their Medsafe approvals in the coming months. Early indicators to monitor include the number of patients enrolled, the clinical outcomes reported, any adverse events documented to the regulator, and whether additional clinicians apply for similar approvals.
Decisions by overseas regulators will shape the broader context. The FDA’s review of MDMA-assisted therapy in the United States, the position of the European Medicines Agency, and any further Australian guidance on training and oversight will all influence the international evidence base and the political pressure on other jurisdictions.
Domestically, attention is likely to focus on whether New Zealand’s Ministry of Health or Pharmac considers funding MDMA-assisted therapy, how professional bodies for psychiatry and psychology develop training and competency standards for any clinicians who may seek approval in future, and whether the section 29 mechanism is used to extend prescribing to additional named psychiatrists.
Conclusion
New Zealand’s approval of two psychiatrists to prescribe MDMA for severe PTSD marks a measured but consequential step in the international debate over psychedelic-assisted therapy. By choosing a narrow, clinician-specific model, Medsafe has prioritized oversight over speed of access and placed the country in a position to gather real-world evidence before considering any broader authorization. The decision will be watched closely by clinicians, patients, and regulators in other jurisdictions, and the early clinical experience of the two approved psychiatrists is likely to shape the next phase of the global conversation about how, and how widely, MDMA-assisted therapy should be made available.
Sources
– https://www.theguardian.com/world/2026/sep/04/new-zealand-approves-mdma-to-treat-severe-ptsd
Source: Guardian International
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Guardian International — source
